Home

EyePoint Pharmaceuticals, Inc. - Common Stock (EYPT)

7.6500
-0.4000 (-4.97%)

Eyepoint Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative treatments for diseases affecting the eye, particularly those related to retinal and intraocular conditions

The company is dedicated to advancing sustained-release drug delivery systems, enabling patients to receive extended therapeutic benefits from their medications with reduced frequency of administration. Eyepoint's portfolio includes specialized formulations that aim to improve patient outcomes and ease the burden of disease management in ocular health. Through its commitment to research and development, Eyepoint seeks to address unmet medical needs in the field of ophthalmology.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close8.050
Open8.040
Bid7.660
Ask7.700
Day's Range7.580 - 8.140
52 Week Range6.900 - 30.99
Volume627,084
Market Cap267.63M
PE Ratio (TTM)-3.844
EPS (TTM)-2.0
Dividend & YieldN/A (N/A)
1 Month Average Volume677,368

News & Press Releases

12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · October 28, 2024
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Lossbenzinga.com
EyePoint Pharmaceuticals' shares rise as interim Phase 2 VERONA trial data shows Duravyu improves visual acuity and anatomy in diabetic macular edema patients.
Via Benzinga · October 28, 2024
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · October 28, 2024
Analyst Ratings For EyePoint Pharmaceuticalsbenzinga.com
Via Benzinga · October 25, 2024
NVIDIA, Trump Media & Technology, Bausch + Lomb, Sirius XM And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · October 14, 2024
EyePoint Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)benzinga.com
Via Benzinga · August 13, 2024
Deep Dive Into EyePoint Pharmaceuticals Stock: Analyst Perspectives (4 Ratings)benzinga.com
Via Benzinga · May 7, 2024
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Sessionbenzinga.com
Via Benzinga · July 12, 2024
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Fridaybenzinga.com
Via Benzinga · July 12, 2024
Crocs To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Mondaybenzinga.com
Via Benzinga · May 13, 2024
Critical Insights From EyePoint Pharmaceuticals Analyst Ratings: What You Need To Knowbenzinga.com
Via Benzinga · March 8, 2024
A Preview Of EyePoint Pharmaceuticals's Earningsbenzinga.com
Via Benzinga · March 6, 2024
EYPT Stock Earnings: EyePoint Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024investorplace.com
EYPT stock results show that EyePoint Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 8, 2024
Flywire Reports Q1 Loss, Joins ZoomInfo, Inspire Medical Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · May 8, 2024
Dow Surges Over 100 Points; EyePoint Pharmaceuticals Shares Plungebenzinga.com
Via Benzinga · May 6, 2024
Spirit Airlines Posts Weak Results, Joins Integra LifeSciences, Bowlero And Other Big Stocks Moving Lower On Mondaybenzinga.com
Via Benzinga · May 6, 2024
Crude Oil Gains 1%; TreeHouse Foods Shares Fall After Q1 Resultsbenzinga.com
Via Benzinga · May 6, 2024
Why Perficient Shares Are Trading Higher By Around 53%? Here Are 20 Stocks Moving In Monday's Mid-Day Sessionbenzinga.com
Via Benzinga · May 6, 2024
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · May 6, 2024
Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Viewsbenzinga.com
Via Benzinga · May 6, 2024
Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?benzinga.com
EyePoint Pharmaceuticals reveals Phase 2 PAVIA trial results for Duravyu in non-proliferative diabetic retinopathy. Positive data showcases Duravyu's efficacy and safety profile.
Via Benzinga · May 6, 2024
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · May 6, 2024
Over $10M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buyingbenzinga.com
Via Benzinga · April 23, 2024
EYPT Stock Earnings: EyePoint Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023investorplace.com
EYPT stock results show that EyePoint Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 7, 2024
Earnings Scheduled For March 7, 2024benzinga.com
Companies Reporting Before The Bell • CI&T (NYSECINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.
Via Benzinga · March 7, 2024